Results 171 to 180 of about 1,744 (184)

Emergency department care of ABSSSI with dalbavancin infusion, direct discharge, and outpatient telemedicine follow up: a study protocol

Journal of Chemotherapy, 2022
Novel therapeutic strategies such as the long-acting lipoglycopeptide antibiotics allow for the treatment and discharge of selected emergency department (ED) patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI), who require intravenous antibiotics and would otherwise be hospitalized.
Durante-Mangoni, Emanuele, Riccardi, Alessandro, Guarino, Mario, Cesaro, Flavio, Lugarà, Marina, Mascolo, Silvia, Morelli, Lucia, Natale, Vincenzo, Andreoni, Massimo   +8 more
openaire   +3 more sources

Delafloxacin meglumine for the treatment of acute bacterial skin and skin structure infections (ABSSSI)

Drugs of Today, 2018
Delafloxacin meglumine (Baxdela, WQ-3034, ABT-492, RX-3341; Melinta Therapeutics) was approved by the U.S. Food and Drug Administration (FDA) in June 2017 for the treatment of acute bacterial skin and skin structure infections on the basis of data from two phase III trials.
G, Kaul, E, Kapoor, A, Dasgupta, S, Chopra   +3 more
openaire   +2 more sources

Tedizolid an Effective Option for Treating ABSSSI

MD Conference Express, 2015
M. Vinall, C. De Anda, W. Joseph, T. Sandison   +3 more
openaire   +1 more source

Lefamulin: Pleuromutilin antibacterial, Treatment of pneumonia and ABSSSI

Drugs of the Future, 2016
null Thakare, R., null Dasgupta, A., null Chopra, S.   +2 more
openaire   +1 more source